Identification of a High-Risk Subgroup of Patients with Resected pT3 Oral Cavity Cancer in Need of Postoperative Adjuvant Therapy
- 162 Downloads
The NCCN 2010 guidelines recommend the use of postoperative adjuvant radiotherapy (RT) for patients with pT3 oral cavity squamous cell carcinoma (OSCC). We sought to determine whether postoperative adjuvant RT improves outcomes in pT3N0 OSCC patients.
A total of 119 consecutive patients with pT3N0 disease were involved. A total of 42 patients received postoperative adjuvant RT, while the remaining 77 did not. The 5-year rates of control, distant metastasis, and survival were the main outcome measures.
We found no differences in the risk profile of patients with and without postoperative adjuvant RT, the only exceptions being a higher frequency of tumor depth ≥10 mm (78.6% vs. 48.0%, P = .001) and close margins ≤4 mm (11.9 % vs. 2.7%, P = .043) in those treated by adjuvant RT. Tumor depth ≥10 mm was the only independent prognostic factor for 5-year local control, disease-free survival, and disease-specific survival in multivariable analysis. Tumor depth ≥13 mm was the only independent prognostic factor for the 5-year rate of distant metastases (16% [7 of 50] vs. 2% [1 of 67]). After stratification for tumor depth and adjuvant RT, patients with pT3N0 disease who received adjuvant RT did not show a survival advantage.
Tumor depth ≥10 mm was the only prognostic factor identified in patients with pT3N0 disease. Adjuvant RT did not improve outcomes in pT3N0 patients, regardless of tumor depth. Patients with pT3N0 and tumor depth ≥13 mm (43% of pT3N0) were at the highest risk for distant metastases.
KeywordsNeck Dissection Perineural Invasion Tumor Depth Verrucous Carcinoma Close Margin
This study was supported by grants CMRPG370061 and CMRPG 370062 from the Chang Gung Memorial Hospital.
- 1.Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM. AJCC cancer staging manual. 7th ed. New York: Springer-Verlag; 2010.Google Scholar
- 2.National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Head and Neck Cancers, V. I. 2010. http://www.nccn.org/. Accessed 21 May 2010.
- 10.Brown JS, Blackburn TK, Woolgar JA, Lowe D, Errington RD, Vaughan ED, et al. A comparison of outcomes for patients with oral squamous cell carcinoma at intermediate risk of recurrence treated by surgery alone or with post-operative radiotherapy. Oral Oncol. 2007;43:764–73.PubMedCrossRefGoogle Scholar
- 13.Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27:843–50.PubMedCrossRefGoogle Scholar
- 18.Rosenthal DI, Harris J, Forastiere AA, Weber RS, Ridge JA, Myers JN, et al. Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024. J Clin Oncol. 2009;27:4727–32.PubMedCrossRefGoogle Scholar